Clinical trials: Cancer, Hematological
Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma
A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies
The purpose of this study is to determine the safety, tolerability, dose limiting toxicities, and maximum tolerated dose of CB-5083 in subjects with lymphoid hematological malignancies.
- Trial name
- CLC-102 (NCT02223598)
- Testing
- CB-5083, Dexamethasone
- Where
- 8 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Cleave Biosciences, Inc.
Multiple Myeloma
A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)
This is a non-randomized, open label, phase I/II, dose-escalation study, involving a single injection of Temferon, an investigational advanced therapy consisting of autologous CD34+-enriched hematopoietic stem and progenitor…
- Trial name
- NCT03875495
- Testing
- Temferon
- Where
- Italy
- Volunteers
- 9 people
- Sponsor
- Genenta Science
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
This is an open-label, non-randomised, multi-centre phase I-II study of CHR-2797 administered orally once a day. The study involves two distinct phases: Phase I: an open-label, dose-escalating phase of the study to explore the…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT00689000
- Testing
- CHR-2797 (tosedostat): Aminopeptidase inhibitor
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Chroma Therapeutics
Castrate Resistant Prostate Cancer, NUT Carcinoma
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
- Conditions
- Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
- Trial name
- NCT05488548
- Testing
- EP31670
- Where
- 6 sites in United States
- Volunteers
- 75 people
- Sponsor
- Epigenetix, Inc.
High Risk Hematological Malignancy, Cord Blood Transplant
US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia
Cord blood (CB) transplants are an option for patients lacking an HLA identical donor but are hampered by low cell dose, prolonged aplasia and high transplant related mortality.
- Trial name
- NCT04103879
- Testing
- ECT-001-CB (UM171-Expanded Cord Blood Transplant)
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 30 people
- Sponsor
- ExCellThera inc.
Relapsed or Refractory Hematological Malignancies
Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies
To define the maximum tolerated dose of oral daily ENMD 2076 in patients with relapsed or refractory hematological malignancies
- Trial name
- NCT00904787
- Testing
- ENMD-2076
- Where
- Canada
- Volunteers
- 27 people
- Sponsor
- CASI pharmaceuticals, Inc.
Hematological Malignancies, Neutropenia
Observational Study Investigating the Response Rate of Itraconazole Injection in Treating Immunocompromised Patients
The purpose of this observational study is to examine the rate at which elevated body temperature (fever) is relieved by an itraconazole injection administrated to patients experiencing neutropenic fever .
- Conditions
- Hematological Malignancies, Neutropenia, Fever
- Trial name
- NCT01060462
- Testing
- Pts. w/ neutropenic fever associated w/ hematologic malignancy
- Volunteers
- 438 people
- Sponsor
- Janssen Korea, Ltd., Korea
Acute Lymphoblastic Leukemia, B Cell Lymphoma
Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies
This is the second stage of the previous anti-CD19 CAR-T therapy (NCT02965092). The study aims to evaluate the safety and efficacy of consolidative allo-HSCT following CAR-T therapy in patients with relapsed or refractory B cell…
- Trial name
- NCT03366350
- Testing
- Allogeneic hematological stem cell transplantation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Wuhan Sian Medical Technology Co., Ltd
Hematological Malignancies, Multiple Myeloma
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies. All patients will receive tinostamustine.
- Conditions
- Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma
- Trial name
- NCT02576496
- Testing
- Tinostamustine
- Where
- 18 sites in United States, France and 5 more
- Volunteers
- 106 people
- Sponsor
- Mundipharma Research Limited
Hematologic Malignancy
A Phase I Study of BR108 in Hematological Malignancies
A Phase I study of BR108 in hematological malignancies
- Trial name
- NCT06018506
- Testing
- BR108 injection
- Where
- China
- Volunteers
- 8 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia, AML
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
The purpose of this study is to evaluate the efficacy and safety of tosedostat in elderly patients suffering from refractory or relapsed AML.
- Trial name
- OPAL (NCT00780598)
- Testing
- Tosedostat
- Where
- 21 sites in United States, Canada and 1 more
- Volunteers
- 76 people
- Sponsor
- Chroma Therapeutics
Graft Versus Host Disease
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients undergoing AHSCT, with radiation or non-radiation…
- Trial name
- NCT01379209
- Testing
- RGI-2001, Calcineurin Inhibitors, Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- 6 sites in United States
- Volunteers
- 68 people
- Sponsor
- Regimmune Corporation
Hematological Malignancies
A Clinical Study of HMPL-506 in Patients With Hematological Malignancies
This is a Phase 1, multicenter, open-label clinical study of HMPL-506 administered orally in the treatment of hematological malignancies.
- Trial name
- NCT06387082
- Testing
- HMPL-506
- Where
- 16 sites in China
- Volunteers
- 132 people
- Sponsor
- Hutchmed
B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory malignant hematological tumors.
- Conditions
- B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma
- Trial name
- NCT07239323
- Testing
- Invivo CAR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in participants with CD20-positive lymphoproliferative disorders.
- Conditions
- CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma
- Trial name
- NCT00788684
- Testing
- rituximab, ABT-263
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- AbbVie
Relapsed/Refractory Chronic Lymphocytic Leukemia
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
An open-label, multicenter, phase Ib/II clinical trial was conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of GNC-035 quad-specific antibody injection in patients with…
- Trial name
- NCT05944978
- Testing
- GNC-035
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
This is a study to assess the safety of increasing dose levels of bexmarilimab when combined with standard of care (SoC) in patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) or acute myeloid…
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory AML
- Trial name
- BEXMAB (NCT05428969)
- Testing
- Bexmarilimab, Azacitidine, Venetoclax
- Where
- 10 sites in United States, Finland and 1 more
- Volunteers
- 181 people
- Sponsor
- Faron Pharmaceuticals Ltd
Solid Tumor, Hematological Malignancy
A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies
The purpose of this study is to evaluate the plasma concentration and pharmacodynamics effects of warfarin 5 mg, in the presence or absence of belinostat 1,000 mg/m².
- Trial name
- NCT01317927
- Testing
- Belinostat, Warfarin
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Solid Tumor, Hematological Malignancies
Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
This is an open-label, extension protocol designed to allow patients to continue to receive belinostat treatment after they have completed the protocol-specified assessments and procedures in a Spectrum sponsored belinostat study…
- Trial name
- NCT04184869
- Testing
- Belinostat, Atazanavir
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Acrotech Biopharma Inc.
Graft Versus Host Disease, Hematologic Malignancies
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation
The main purpose of this study is to evaluate the effect of palifermin versus placebo in the reduction of severe acute graft versus host disease (GVHD) and severe oral mucositis.
- Trial name
- NCT00189488
- Testing
- Palifermin, Conditioning Regimen, Allogeneic stem cell transplant
- Volunteers
- 155 people
- Sponsor
- Swedish Orphan Biovitrum